Prostate-specific antigen (PSA) measurements' association with metastasis and mortality in patients with nmCRPC (non-metastatic castration resistant prostate cancer).

被引：1
|
作者：
Li, Sophia
Ding, Zhijie
Lin, Jennifer H.
Behl, Ajay S.
Pericone, Chris
Deshmukh, Siddhant
Macomson, Brian
Shore, Neal D.
机构：
[1] Janssen Sci Affairs LLC, Horsham, PA USA
[2] Janssen Sci Affairs LLC, Titusville, NJ USA
[3] Mu Sigma Business Solut Pvt Ltd, Bengaluru, India
[4] Carolina Urol Res Ctr, Myrtle Beach, SC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e17058
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17058
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer
    Xu Steven Xu
    Charles J. Ryan
    Kim Stuyckens
    Matthew R. Smith
    Fred Saad
    Thomas W. Griffin
    Youn C. Park
    Margaret K. Yu
    Peter De Porre
    An Vermeulen
    Italo Poggesi
    Partha Nandy
    Clinical Pharmacokinetics, 2017, 56 : 55 - 63
  • [42] Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer
    Angelergues, Antoine
    Maillet, Denis
    Flechon, Aude
    Ozguroglu, Mustafa
    Mercier, Florence
    Guillot, Aline
    Le Moulec, Sylvestre
    Gravis, Gwenaelle
    Beuzeboc, Philippe
    Massard, Christophe
    Fizazi, Karim
    Rouge, Thibault de La Motte
    Delanoy, Nicolas
    Elaidi, Reza-Thierry
    Oudard, Stephane
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (09) : 1602 - 1609
  • [43] Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging?
    Bikkasani, Krishna
    Qin, Qian
    Zhong, Xiaobo
    Lin, Justin
    Galsky, Matthew D.
    Oh, William K.
    Tsao, Che-Kai
    CLINICAL GENITOURINARY CANCER, 2021, 19 (06) : E346 - E351
  • [44] Efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) > and ≤ 6 months
    Schostak, Martin
    Boegemann, Martin
    Smith, Matthew R.
    Shore, Neal D.
    Tammela, Teuvo L. J.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Le Berre, Marie-Aude
    Snapir, Amir
    Sarapohja, Toni
    Fizazi, Karim
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 105 - 105
  • [45] Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS
    Morgans, Alicia K.
    Sweeney, Christopher
    Wallis, Christopher J. D.
    Halabi, Susan
    Armstrong, Andrew J.
    Adorjan, Patrick
    Ghadessi, Mercedeh
    Verholen, Frank
    Grimm, Marc-Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Prostate-specific antigen velocity and prostate-specific antigen slope compared for prostate cancer diagnosis in men with 3 or more PSA measurements
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 239 - 239
  • [47] Ethinylestradiol Improves Prostate-specific Antigen Levels in Pretreated Castration-resistant Prostate Cancer Patients
    Izumi, Kouji
    Kadono, Yoshifumi
    Shima, Takashi
    Konaka, Hiroyuki
    Mizokami, Atsushi
    Koh, Eitetsu
    Namiki, Mikio
    ANTICANCER RESEARCH, 2010, 30 (12) : 5201 - 5205
  • [48] PROSPER: A phase 3 study of enzalutamide (ENZA) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
    Tombal, B.
    Hussain, M.
    Fizazi, K.
    Saad, F.
    Rathenborg, P.
    Shore, N. D.
    Demirhan, E.
    Modelska, K.
    Phung, D.
    Krivoshik, A.
    Sternberg, C. N.
    SWISS MEDICAL WEEKLY, 2018, 148 : 15S - 15S
  • [49] Real-world analysis of prostate-specific antigen (PSA) outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA)
    Freedland, Stephen J.
    Schultz, Neil M.
    Coutinho, Anna D.
    Fuldeore, Rupali
    Hedlund, Nancy
    Feng, Qi
    Ramaswamy, Krishnan
    Hong, Agnes
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [50] Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study
    Hara, Shuhei
    Mori, Keiichiro
    Fukuokaya, Wataru
    Tomomasa, Naoya
    Oguchi, Takahiro
    Takahashi, Yusuke
    Saito, Shun
    Katami, Jun
    Sano, Takayuki
    Kadena, Soushi
    Hashimoto, Masaki
    Yata, Yuji
    Nishi, Eriko
    Suhara, Yushi
    Takamizawa, Shigeyoshi
    Kurawaki, Shiro
    Suzuki, Hirotaka
    Miyajima, Keiichiro
    Iwatani, Kosuke
    Urabe, Fumihiko
    Ito, Kagenori
    Yanagisawa, Takafumi
    Tsuzuki, Shunsuke
    Shimomura, Tatsuya
    Kimura, Takahiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (08) : 1191 - 1197
12345